Evidence map›Paper›PMID 39880288›Full record

ArticleJournal of substance use and addiction treatment2025

The impact of buprenorphine prescriber data on geospatial access to treatment in HEALing Communities Study communities, 2022.

Daniel R Harris, Shikhar Shrestha, Peter Rock, Anita Silwal, Gia Barboza-Salerno, Olivia Lewis, Sumeeta Srinivasan, Thomas J Stopka

Abstract read
In one paragraph

Article in Journal of substance use and addiction treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Daniel R HarrisInstitute for Biomedical Informatics, University of Kentucky, Lexington, KY, United States of America. Electronic address: daniel.harris@uky.edu.
Shikhar ShresthaDepartment of Public Health and Community Medicine, Tufts University School of Medicine, Boston, MA 02111, United States of America.
Peter RockSubstance Use Priority Research Area, University of Kentucky, Lexington, KY, United States of America.
Anita SilwalSubstance Use Priority Research Area, University of Kentucky, Lexington, KY, United States of America; School of Community Health Sciences, Counseling and Counseling Psychology, Oklahoma State University, Stillwater, OK, United States of America.
Gia Barboza-SalernoColleges of Social Work and Public Health, The Ohio State University, Columbus, OH 43012, United States of America.
Olivia LewisDepartment of Public Health and Community Medicine, Tufts University School of Medicine, Boston, MA 02111, United States of America.
Sumeeta SrinivasanDepartment of Urban and Environmental Policy and Planning, Tufts University, Medford, MA 02155, United States of America.
Thomas J StopkaDepartment of Public Health and Community Medicine, Tufts University School of Medicine, Boston, MA 02111, United States of America.

Funding

MassHEAL - Reducing overdose deaths by 40% (2019-2023)UM1DA049412 · NIDA · BOSTON MEDICAL CENTER · PI SAMET, JEFFREY H. · 2019 to 2023
$82.9M
Kentucky CAN HEAL (Communities and Networks Helping End Addiction Long-term)UM1DA049406 · NIDA · UNIVERSITY OF KENTUCKY · PI WALSH, SHARON L. · 2019 to 2022
$81.7M
Optimizing HEALing in Ohio Communities (OHiO)-Health Equity SupplementUM1DA049417 · NIDA · OHIO STATE UNIVERSITY · PI FREISTHLER, BRIDGET J, WINHUSEN, T JOHN · 2019 to 2023
$66.3M
NIDA NIH HHS UM1 DA049406NIDA NIH HHS UM1 DA049412NIDA NIH HHS UM1 DA049417
6 · The paper itself

Abstract

introductionThe location of buprenorphine treatment providers in the United States is pivotal to the understanding of regional factors associated with prescription and uptake. We evaluated how distinct data sources of treatment providers and their associated locations contribute to the differences observed when measuring buprenorphine accessibility.

methodsWe compared buprenorphine treatment provider data from the Drug Enforcement Administration (DEA) and data from the behavioral health treatment locator from the Substance Abuse and Mental Health Services Administration (SAMHSA) for July 2022. Both DEA and SAMHSA data, while similar in spirit, vary substantially in how and why each data set is collected. DEA registration was required by law, while SAMHSA data was an opt-in registry of provider-submitted details. Analyzing the underlying semantics of the data is important for understanding the contextual factors driving observable differences in analytical outputs. We measured accessibility using enhanced two-step floating catchment area (E2SFCA) analysis in three states participating in the HEALing Communities Study (Kentucky, Ohio, Massachusetts). Within communities, we compared decile rankings of accessibility per census tract using each data source. We linked prescribing data from Kentucky's prescription drug monitoring program (PDMP) to measure accessibility using providers prescribing buprenorphine. We explored the significance of localized rank exchanges using neighbor set local indicators of mobility association (LIMA).

resultsThe number and rate of providers per capita differed substantially at the community level between data sources in the three states. These differences were less impactful in the spatial context of buprenorphine accessibility, which required both supply and demand in regions smaller than our intervention communities. Shifts did occur when measuring the intercommunity decile ranking of accessibility of census tracts, but LIMA results indicated that these rank exchanges were not significant.

conclusionsWhen analyzing accessibility within a community using E2SFCA analyses, either DEA or SAMHSA data sources are acceptable; linkage to Kentucky's PDMP demonstrated that SAMHSA provider data is equally suitable to PDMP data for research studies involving spatial relationships with providers while being both significantly easier to obtain and less sensitive. When analyzing treatment provider rates per capita, results may vary substantially across these different data sources. Therefore, context must be considered when choosing an appropriate data source to use.

Indexed as

BuprenorphineHealth Services AccessibilityNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersHumansUnited StatesUnited States Substance Abuse and Mental Health Services AdministrationBuprenorphineNarcotic AntagonistsAccessibilityBuprenorphineSpatial AccessTreatment locations

Identifiers

PMID39880288
PMCPMC11908932

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.